Skip to content

Polypharmacy-related Adverse Events in Critically Ill Children

Investigating Polypharmacy-related Adverse Events in Critically Ill Children

Status
Withdrawn
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03293927
Enrollment
0
Registered
2017-09-26
Start date
2018-04-09
Completion date
2019-07-01
Last updated
2019-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Delirium

Keywords

children, mechanically ventilated, fentanyl, dexmedetomidine, delirium, polypharmacy

Brief summary

The purpose of this study is to learn how 2 medications (fentanyl and dexmedetomidine) affect how sick children think and interact with their environments.

Interventions

DRUGFentanyl

The patient will receive IV fentanyl

DRUGDexmedetomidine

The patient will receive IV dexemedetomidine

Sponsors

Duke University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
2 Years to 17 Years
Healthy volunteers
No

Inclusion criteria

* Ages 2-\<18 at the time of enrollment * Admitted to the Duke PICU or PCICU * Planned or anticipated mechanically ventilation for ≥2 days * Require sedation to maintain mechanical ventilation * No contraindication to receipt of fentanyl or dexmedetomidine per clinician judgment * Availability and willingness of the parent/legal guardian to provide written informed consent

Exclusion criteria

* Any concomitant condition, which in the opinion of the investigator would preclude a subject's participation in the study. * Previous participation in this study * Planned receipt of sedatives other than fentanyl or dexmedetomidine * Participants with any of the following diagnoses: traumatic brain injury, intracranial hemorrhage, baseline neurodevelopmental delay, status epilepticus, or requiring inotropic support for hemodynamic stability. * Renal failure requiring renal replacement therapy * Hepatic failure * Support with extracorporeal membrane oxygenation

Design outcomes

Primary

MeasureTime frame
Change in delirium scores as measured by CAPD scoreup to 10 days

Secondary

MeasureTime frame
Drug level associated with CAPD scoreup to 10 days

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026